Ixovex-1 Single Agent and Combination Therapy

Summary

This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection. This will be assessed in patients with palpable locally advanced, unresectable, or metastatic tumours, for whom all approved therapeutic options have been exhausted, are not available, are unlikely to have significant clinical benefit, or are declined by the patient.

Timeline

Start

2024-12-17

Primary completion

2027-01-30

Completion

2027-01-30

Publications

• Background Anwar M, Arendt ML, Ramachandran M, Carlsson A, Essand M, Akusjarvi G, Alusi G, Oberg D. Ixovex-1, a novel oncolytic E1B-mutated adenovirus. Cancer Gene Ther. 2022 Nov;29(11):1628-1635. doi: 10.1038/s41417-022-00480-3. Epub 2022 May 20.

Drugs

Indications